Narrowing the Gap: Access to HIV Treatments in Developing Countries. a Pharmaceutical Company's Perspective
Journal of Medical Ethics. 2000 Feb; 26(1): 47-50.
The advent of new antiretroviral medicines means that the effects of HIV can now be curbed, but only one in twenty infected people have so far benefited. For those living in developing countries, the new treatments are practically unattainable. Governments, UNAIDS and pharmaceutical companies recognise this only too well and have rethought established assumption in order to try and overcome the challenges posed by cost, inadequate health services and unreliable local supply of medicines.
Showing items related by title, author, creator and subject.
Dowsett, Sherie A; Van Campen, Luann E; Bednar, Lisa A (2010-06)BACKGROUND: The scientific publishing practices of the pharmaceutical industry have been heavily criticized in recent years due to the inherent conflict of interest that arises when a pharmaceutical company publishes ...